|
Clinical manifestation
a
|
Sensitivity (95% CI)
|
Specificity (95% CI)
|
Positive predictive value (95% CI)
|
Negative predictive value (95% CI)
|
|---|
|
Diffuse subtype
|
14.7% (11.2 to 18.8%)
|
82.5% (73.4 to 89.5%)
|
75.4% (63.5 to 84.9%)
|
20.9% (17.0 to 25.4%)
|
|
Joint contracture
|
30.7% (23.8 to 38.3%)
|
93.7% (90.2 to 96.2%)
|
73.9% (61.9 to 83.8%)
|
69.9% (65.0 to 74.5%)
|
|
Synovitis
|
22.5% (14.6 to 32.0%)
|
86.7% (82.7 to 90.1%
|
31.9% (21.2 to 44.2%)
|
80.1% (75.7 to 84.0%)
|
|
Myositisb
|
50.0% (6.8 to 93.2%)
|
85.0% (81.4 to 88.2%)
|
2.9% (0.4 to 10.1%)
|
99.5% (98.1 to 99.9%)
|
|
Systemic hypertension
|
21.6% (16.0 to 28.1%)
|
89% (84.5 92.6%)
|
59.4% (46.9 to 71.1%)
|
60.3% (55.1 to 65.3%)
|
|
Renal crisis
|
70.8% (48.9 to 87.4%)
|
87.8% (84.3 to 90.8%)
|
24.6% (15.1 to 36.5%)
|
98.2% (96.3 to 99.3%)
|
|
Malignancyb (all types)
|
21.9% (12.5 to 34.0%)
|
85.8% (81.9 to 89.1%)
|
20.3% (11.6 to 31.7%)
|
86.9% (83.1 to 90.1%)
|
|
Malignancyb,c (certain types)
|
20.8% (10.5 to 35.0%)
|
85.8% (81.9 to 89.1%)
|
15.4% (7.6 to 2.6%)
|
89.7% (86.2 to 92.6%)
|
|
Malignancy within 5 years of SSc onsetc
|
37.5% (15.2 to 64.6%)
|
86.2% (81.7 to 90.0%)
|
13.3% (5.1 to 16.8%)
|
96.1% (92.9 to 98.1%)
|
- anti-RNAP, anti-RNA polymerase III antibodies; CI, confidence interval; SSc, systemic sclerosis. aEver from disease onset to most recent visit; except for malignancy, which was ever from birth to most recent visit. bChi-square P > 0.05 in univariate analysis. cExcluding nonmelanoma skin cancers and the 'other' category.
